Review



srage elisa  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems srage elisa
    Basal solubilized receptor for advanced glycation end products <t>(sRAGE;</t> A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).
    Srage Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 120 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+RAGE+Quantikine+ELISA+Kit/med_rxiv__2025__09__10__25335517-90-4-7
    Average 95 stars, based on 120 article reviews
    srage elisa - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Aerobic Exercise Training Elevates Circulating sRAGE via Modulation of Sheddase Regulation in Adults with Type 2 Diabetes"

    Article Title: Aerobic Exercise Training Elevates Circulating sRAGE via Modulation of Sheddase Regulation in Adults with Type 2 Diabetes

    Journal: medRxiv

    doi: 10.1101/2025.09.10.25335517

    Basal solubilized receptor for advanced glycation end products (sRAGE; A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).
    Figure Legend Snippet: Basal solubilized receptor for advanced glycation end products (sRAGE; A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).

    Techniques Used: Control, Two Tailed Test

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy.
    Article Snippet: .. Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction. ..

    Article Title: A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women
    Article Snippet: Measurement of circulating levels of CML-AGE, sRAGE, and other biomarkers Citrate-plasma was used for measuring CML-AGE using a commercially available ELISA kit (Microcoat Biotechnologie Company, Bernried, Germany). .. Serum or EDTA-plasma was used for measuring sRAGE using human sRAGE Quantikine ELISA kit (R&D System Inc., Minneapolis, MN). ..

    Article Title: Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome
    Article Snippet: Matthieu Jabaudon 1,2 , Raiko Blondonnet 1,2 , Laurence Roszyk 2,3 , Damien Bouvier 2,3 , Jules Audard 1 , Gael Clairefond 2 , Mathilde Fournier 4 , Geoffroy Marceau 2,3 , Pierre Déchelotte 5 , Bruno Pereira 6 , Vincent Sapin 2,3 and Jean-Michel Constantin 1,2 1 CHU Clermont-Ferrand, Intensive Care Unit, Department of Anesthesiology, Critical Care and Perioperative Medicine, Estaing University Hospital, Clermont-Ferrand, France 2 Clermont Université, Université d'Auvergne, EA 7281, R2D2, Clermont-Ferrand, France 3 CHU Clermont-Ferrand, Department of Medical Biochemistry and Molecular Biology, Clermont-Ferrand, France 4 CHU Clermont-Ferrand, Department of Microbiology, Clermont-Ferrand, France 5 CHU Clermont-Ferrand, Department of Pathology, Estaing University Hospital, ClermontFerrand, France 6 CHU Clermont-Ferrand, Department of Clinical Research and Innovation (DRCI), Clermont-Ferrand, France Corresponding author and address for reprints: Matthieu Jabaudon, M.D., M.Sc.. Department of Anesthesiology, Critical Care and Perioperative Medicine, Intensive Care Unit, Estaing University Hospital Clermont Université, Université d'Auvergne, EA 7281, R2D2, Clermont-Ferrand, France Copyright © 2015 by the American Thoracic Society 2 CHU Clermont-Ferrand, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France (Tel) +33 473 750 501 (Fax) +33 473 750 500 (Mail) mjabaudon@chu-clermontferrand.fr

    Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy
    Article Snippet: .. Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction. ..

    Article Title: A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women
    Article Snippet: .. We used human sRAGE Quantikine ELISA kit (R&D System Inc., Minneapolis, MN) to measure sRAGE concentrations. .. We used the R&D Human Obesity MultiAnalyte Profiling Kit (R&D System Inc.) to concomitantly measure concentrations of adiponectin, leptin, MCP1, and PAI1.

    Article Title: Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women’s Health Initiative Study
    Article Snippet: .. In two previous nested case-control studies within the WHI, we measured baseline serum levels of sRAGE [ , ] using human sRAGE Quantikine ELISA kit (R&D System Inc., Minneapolis, MN, USA) at BCM. ..

    other:

    Article Title: Importance of Lung Epithelial Injury in COVID-19–associated Acute Respiratory Distress Syndrome: Value of Plasma Soluble Receptor for Advanced Glycation End-Products
    Article Snippet: A commercially available sandwich enzyme immunoassay kit (Human sRAGE Quantikine ELISA Kit; R&D Systems) was used following recommendations from the manufacturer.



    Similar Products

    srage elisa  (R&D Systems)
    95
    R&D Systems srage elisa
    Basal solubilized receptor for advanced glycation end products <t>(sRAGE;</t> A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).
    Srage Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+RAGE+Quantikine+ELISA+Kit/med_rxiv__2025__09__10__25335517-90-4-7
    Average 95 stars, based on 1 article reviews
    srage elisa - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    human srage quantikine elisa kit  (R&D Systems)
    95
    R&D Systems human srage quantikine elisa kit
    Plasma concentrations of AGEs ( A ), <t>sRAGE</t> ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.
    Human Srage Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+RAGE+Quantikine+ELISA+Kit/pmc11852413-113-17-22
    Average 95 stars, based on 1 article reviews
    human srage quantikine elisa kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    r d systems srage kit  (R&D Systems)
    95
    R&D Systems r d systems srage kit
    Plasma concentrations of AGEs ( A ), <t>sRAGE</t> ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.
    R D Systems Srage Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+Myeloperoxidase+Quantikine+ELISA+Kit/pmc11853316-170-197-197
    Average 95 stars, based on 1 article reviews
    r d systems srage kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    total plasma srage  (R&D Systems)
    95
    R&D Systems total plasma srage
    Plasma concentrations of AGEs ( A ), <t>sRAGE</t> ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.
    Total Plasma Srage, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+RAGE+Quantikine+ELISA+Kit/pm37985201-75-0-8
    Average 95 stars, based on 1 article reviews
    total plasma srage - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    plasma srage  (R&D Systems)
    95
    R&D Systems plasma srage
    Plasma concentrations of AGEs ( A ), <t>sRAGE</t> ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.
    Plasma Srage, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+srage+quantikine+elisa+kit/Human+RAGE+Quantikine+ELISA+Kit/pm37985201-75-1-8
    Average 95 stars, based on 1 article reviews
    plasma srage - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Basal solubilized receptor for advanced glycation end products (sRAGE; A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).

    Journal: medRxiv

    Article Title: Aerobic Exercise Training Elevates Circulating sRAGE via Modulation of Sheddase Regulation in Adults with Type 2 Diabetes

    doi: 10.1101/2025.09.10.25335517

    Figure Lengend Snippet: Basal solubilized receptor for advanced glycation end products (sRAGE; A), solubilized Toll-like receptor 4 (sTLR4, C) pre and post 12-week intervention in the control (CON) and aerobic exercise training (AE) groups. Respective absolute changes in basal sRAGE (B) and sTLR4 (C) and percentage changes in sRAGE (E) and sTLR4 (E) were calculated. *P < 0.05 vs Pre, # P < 0.05 vs CON. Statistical analyses performed include mixed model regression analyses with Bonferroni post hoc (panels A & C) and two-tailed t-test (panels B, D, & E).

    Article Snippet: sRAGE was quantified via sRAGE ELISA (DRG000, R&D Systems, Minneapolis, MN) according to manufacturer’s instructions.

    Techniques: Control, Two Tailed Test

    Plasma concentrations of AGEs ( A ), sRAGE ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.

    Journal: Biomedicines

    Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

    doi: 10.3390/biomedicines13020438

    Figure Lengend Snippet: Plasma concentrations of AGEs ( A ), sRAGE ( B ), and AGE/sRAGE ratio ( C ) in patients with type 2 diabetes with neuropathy before and after six months of 600 mg/day alphalipoic acid (ALA) treatment and in diabetic controls without neuropathy. Solid lines represent medians. Magenta dots represent data from neuropathic patients before ALA treatment, green dots represent data from neuropathic patients after six months of ALA treatment, and grey dots represent data of age-, gender-, and BMI-matched diabetic controls. p -values were calculated by the Wilcoxon matched paired test in neuropathic patients before and after ALA, and by the Mann–Whitney U -test between neuropath patients and diabetic controls. Abbreviations: ALA, alphalipoic acid; AGE, advanced glycation end product; AU, autofluorescence; sRAGE, soluble receptor of advanced glycation end products.

    Article Snippet: Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction.

    Techniques: Clinical Proteomics, MANN-WHITNEY

    Correlations of AGE and sRAGE with vascular markers in neuropathic patients before and after ALA treatment.

    Journal: Biomedicines

    Article Title: Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

    doi: 10.3390/biomedicines13020438

    Figure Lengend Snippet: Correlations of AGE and sRAGE with vascular markers in neuropathic patients before and after ALA treatment.

    Article Snippet: Day-to-day variation (5 days) was 10.5% (n = 35). sRAGE levels were measured by the ELISA method (Human sRAGE Quantikine ELISA kit, R&D Systems Europe Ltd., Abington, UK) according to the manufacturer’s instruction.

    Techniques: